News and Events

Subscribe to our press distribution list to receive the latest news about AMW.

Upcoming

Events

No events available

Past

Events

Archive

Pharmapack

January 24-25, 2024 Paris, France https://www.pharmapackeurope.com/

Pharmasynergy

February 08-09, 2024
London, UK

euroPLX84

February 26-27, 2024 Lisbon, Portugal

BIO-Europe Spring

March 18-20, 2024
Barcelona, Spain
https://informaconnect.com/bioeurope-spring/

4th Wet AMD & Diabetic Eye Disease Drug Development

March 19-21, 2024
Boston, MA
https://wet-amd-drug-development.com/

BIO International Convention

June 03-06, 2024
San Diego, California
https://www.bio.org/events/bio-international-convention

CPHI South East Asia

July 10-12, 2024 Bangkok, Thailand https://www.cphi.com/sea/en/home.html

CPHI 2024

October 08-10, 2024 Milan, Italy https://www.cphi.com/europe/en/home.html

PODD – Partnership Opportunities in Drug Delivery

October 28-29, 2024 Boston, USA https://poddconference.com

BIO-Europe

November 04-06, 2024 Stockholm, Sweden https://informaconnect.com/bioeurope/

Latest

News

29. December 2020

A thank you for the employees and region

First no company outing, then no Christmas party. Corona has also ruined beautiful traditions at the pharmaceutical developer AMW from Warngau. However, the company has created a replacement. Monday before Christmas, some employees were amazed when two Santas were in front of the camera with a history book to tune in to a Christmas Day via video message.

2. November 2020

Expansion of the partnership between AMW and Zentiva for Western Europe

Zentiva will include the leuprorelin implant to its portfolio for selected markets in Western Europe. This implant is another successful product of AMW, developed and produced by AMW The leuprorelin implant for the treatment of prostate cancer received its first marketing authorisation in Germany in 2018 and gained market share quickly.

1. May 2020

AMW GmbH realigns management

Dr. Wilfried Fischer, founding shareholder of AMW, has retired from the management board and remains associated with the company as an important shareholder. His areas of responsibility will be taken over by the previous Co-Managing Directors Dr. Friedrich Tegel and Philipp Karbach.

26. December 2019

AMW GmbH from Warngau continues to grow and establishes an advisory board

More than 100 people are now employed at the pharmaceutical plant in Warngau. In addition to the implants Goserelin and Leuprorelin and the patches Buprenorphin and Rivastigmine, the specialty pharmaceutical company developed a generic version of MSD’s Nuvaring contraceptive ring to market maturity. AMW is thus setting new standards in contraception. In order to improve its scientific and technical position, AMW has established an advisory board consisting of Dr. Georg Ingram, Dr. Dirk Schrader and Prof. Dr. Gerhard Winter.

21. December 2017

Brussels, 21 December 2017: Investment Plan for Europe: EIB lends to AMW GmbH in Warngau

The European Investment Bank (EIB) is providing EUR 25 million to AMW GmbH (AMW). AMW is a specialist pharmaceutical company that specializes in novel drug delivery systems. With the money, AMW will be able to expand the development of innovative medicines, carry out clinical trials and expand its production capacity at its plant in Warngau in Upper Bavaria as well as at its subsidiary Endomedica (Halle, Saxony-Anhalt). A new building for research, development and production with special manufacturing technology and state-of-the-art laboratory equipment is to be built at the company headquarters in Warngau.

For press and news inquiries please send an e-mail to news@a-m-w.eu